300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. Issue 3 (September 2015) - Rasco, D.W.; Middleton, M.R.; Gonzalez, R.; Corrie, P.; Pavlick, A.; Lorigan, P.; Plummer, R.; Gore, M.; Herbert, C.; Agarwala, S.S.; Logan, T.F.; Khleif, S.N.; et al.